Background:Purpose of current study was to study the ocular manifestations in beta-thalassemia major patients and assess the ocular side-effects of iron chelating agents.Methods: Cross sectional study included 45 β Thalassemia major patients from age group of 6months to 12 years were taken. Full medical history, thorough physical examinations were done to all patients groups, and ophthalmological examination to determine the prevalence of ocular manifestations for all patient groups and to correlate these manifestations or changes with iron chelating agents.Results:In 45 patients (22 males and 23 females) with age ranging between 2 years to 12 years, ocular involvement is seen in 35% in the form of decreased visual acuity 26%, tortuous bloo...
Background: Thalassemia is a major health problem in developing and developed countries and suffers ...
Background: Regular blood transfusion and iron chelation therapy has increased life span of children...
About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops ret...
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients ...
Introduction: The current article mainly attempts to evaluate the incidences of ocular toxicity and ...
Background: Beta thalassemia (β-thalassemia) is a hereditary disease caused by defective globin syn...
Background: Thalassemia is a globally prevalent genetic disorder. Patients with thalassemia are pron...
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural ...
Introduction In Pakistan, the reported carrier rate of thalassaemia is estimated to be 5%–8% with 50...
Transfusion dependent thalassemia is a hematological condition characterized by imbalance in synthes...
Abstract:Background: Major thalassemia is the most inherited hemoglobinopathy that caused severe and...
INTRODUCTION: Beta-thalassemias are a group of hereditary blood disorders characterized by absence o...
Background: Anemia is a major public health problem with total prevalence of 30%. It is one of the h...
Introduction: Thalassemia is a genetic condition and is one of the commonest single-gene hereditary ...
Background and Aim: Beta thalassemia has a spectrum of varied manifestations and complications. Surv...
Background: Thalassemia is a major health problem in developing and developed countries and suffers ...
Background: Regular blood transfusion and iron chelation therapy has increased life span of children...
About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops ret...
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients ...
Introduction: The current article mainly attempts to evaluate the incidences of ocular toxicity and ...
Background: Beta thalassemia (β-thalassemia) is a hereditary disease caused by defective globin syn...
Background: Thalassemia is a globally prevalent genetic disorder. Patients with thalassemia are pron...
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural ...
Introduction In Pakistan, the reported carrier rate of thalassaemia is estimated to be 5%–8% with 50...
Transfusion dependent thalassemia is a hematological condition characterized by imbalance in synthes...
Abstract:Background: Major thalassemia is the most inherited hemoglobinopathy that caused severe and...
INTRODUCTION: Beta-thalassemias are a group of hereditary blood disorders characterized by absence o...
Background: Anemia is a major public health problem with total prevalence of 30%. It is one of the h...
Introduction: Thalassemia is a genetic condition and is one of the commonest single-gene hereditary ...
Background and Aim: Beta thalassemia has a spectrum of varied manifestations and complications. Surv...
Background: Thalassemia is a major health problem in developing and developed countries and suffers ...
Background: Regular blood transfusion and iron chelation therapy has increased life span of children...
About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops ret...